Cambrex Corp Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/15/2019)
| Balance Sheet | Total Assets | 1,223,430,000.00 | ROE | – |
| Balance Sheet | Total Equity | 653,727,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -62,598,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 24,384,000.00 | – | – |
| Cashflow | Operating Cash Flow | 86,982,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 2.75 | Div. Yield | – |
| Income | Net Income | 92,418,000.00 | P/E | – |
| Income | Shares Outstanding | 33,665,000.00 | P/B | – |
| Income | Total Revenue | 532,093,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Cambrex Corporation (the "Company" or "Cambrex"), a Delaware corporation, began business in December 1981. Cambrex is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company's overall strategy is to: grow its portfolio of custom development projects, especially those in the later stages of the clinical trial process; secure long-term supply agreements to produce active pharmaceutical ingredients (“APIs”) and intermediates for newly approved drug products; expand sales of products and projects based on its proprietary technologies; partner with generic drug companies to grow the Company’s extensive portfolio of generic APIs; and develop, or co-develop with partners, a portfolio of niche generic drug products in finished dosage form. The Company also seeks to demonstrate excellence in regulatory compliance, environmental, health and safety, and customer service. Cambrex has four operating segments, which are manufacturing facilities that have been aggregated as one reportable segment.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.cambrex.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more